Feasibility of daily pain measurement using text messages in hidradenitis suppurativa clinical trials; data from the THESEUS study.

Competing Interests: Conflicts of interest R.C.-J. was a NIHR HTA Associate Board Member (May 2018 to March 2020). F.C. is a consultant for UCB Pharma and received a fee from Daylong for participating in a hidradenitis suppurativa consensus meeting. L.H. has received consultancy fees from the University of Oxford for an educational grant funded by Pfizer, unrelated to the submitted work. K.H. is a member of the NIHR Research Professors Panel (2019–­present), and was a member of the NIHR HTA General Committee (2016–22) and the NIHR HTA Funding Committee Policy Group (2017–22). J.R.I. receives a stipend as Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate. He is a consultant for Abbvie, Boehringer Ingelheim, ChemoCentryx, Citryll, MoonLake, Novartis, UCB Pharma and UNION Therapeutics, and has served on advisory boards for Insmed, Kymera Therapeutics and Viela Bio. He is co-copyright holder of HiSQOL, Investigator Global Assessment and Patient Global Assessment instruments for HS. His department receives income from the copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments.